Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Galepharm is a Swiss pharmaceutical company headquartered in Küsnacht, specializing in the marketing and distribution of specialty medicines with a core focus on endocrinology. The company is a key provider of thyroid hormone replacement therapies, most notably Tirosint (levothyroxine), which is formulated as a liquid-filled softgel capsule to enhance bioavailability and consistency. Galepharm works closely with manufacturing partners like IBSA Institut Biochimique SA to bring innovative delivery forms of established molecules to the Swiss and European markets. Their business model centers on providing high-quality, reliable treatments for chronic conditions, particularly those requiring precise hormonal regulation. Additionally, Galepharm emphasizes clean formulations that are free from common allergens such as gluten and lactose, catering to patients with specific sensitivities.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Galepharm.